Ergoteles’s Syndax Pharmaceuticals SNDX Stock Holding History

Ergoteles’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-68,764	Closed	-$1.44M	–	724
2023 Q2	$1.44M	Buy	+68,764	New	+$1.43M	0.07%	354
2022 Q1	–	Sell	-34,997	Closed	-$766K	–	1607
2021 Q4	$766K	Sell	34,997 -12,071	-26%	-$223K	0.03%	495
2021 Q3	$899K	Buy	+47,068	New	+$784K	0.03%	407

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Ergoteles's SNDX Position: Q3 2023 in Review

Ergoteles sold out of Syndax Pharmaceuticals (SNDX) in Q3 2023, closing a stake of 68,764 shares — an estimated $1.44M sold.

Ergoteles first reported a position in SNDX in Q3 2021 and held it in 3 quarters. The position peaked at $1.44M in Q2 2023. 175 funds tracked by Wall St. Rank hold SNDX as of Q3 2023.

Ergoteles reported no remaining Syndax Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 68,764 Syndax Pharmaceuticals shares in Q3 2023, an estimated $1.44M.
Ergoteles first reported a position in Syndax Pharmaceuticals in Q3 2021 and held it in 3 quarters.
Ergoteles's Syndax Pharmaceuticals position peaked at $1.44M in Q2 2023.
175 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.